Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity

El-Banna, Hanaa Samy; Khouly, Radwa Mostafa El; Gado, Souzan Ezzat

doi:10.1007/s10067-019-04899-2

Cited by 6 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, higher levels of these factors in SLE patients may be associated with epigenetic changes due to DNA hypomethylation [220]. Interestingly, IL-34, strongly related to myeloid cell subsets (e.g., brain microglia), appears to be associated with disease progression, severity, and chronicity [221,222]. Therefore, blocking NGF, IL-13, and/or IL-34 might be considered to suppress the expression of proinflammatory cytokines in the blood of SLE patients, potentially benefiting the patient's condition.…”

Section: Systemic Lupus Erythematosusmentioning

confidence: 99%

Nerve Growth Factor and Autoimmune Diseases

Terracina,

Ferraguti,

Tarani

et al. 2023

CIMB

View full text Add to dashboard Cite

NGF plays a crucial immunomodulatory role and increased levels are found in numerous tissues during autoimmune states. NGF directly modulates innate and adaptive immune responses of B and T cells and causes the release of neuropeptides and neurotransmitters controlling the immune system activation in inflamed tissues. Evidence suggests that NGF is involved in the pathogenesis of numerous immune diseases including autoimmune thyroiditis, chronic arthritis, multiple sclerosis, systemic lupus erythematosus, mastocytosis, and chronic granulomatous disease. Furthermore, as NGF levels have been linked to disease severity, it could be considered an optimal early biomarker to identify therapeutic approach efficacy. In conclusion, by gaining insights into how these molecules function and which cells they interact with, future studies can devise targeted therapies to address various neurological, immunological, and other disorders more effectively. This knowledge may pave the way for innovative treatments based on NGF manipulation aimed at improving the quality of life for individuals affected by diseases involving neurotrophins.

show abstract

Section: Systemic Lupus Erythematosusmentioning

confidence: 99%

Nerve Growth Factor and Autoimmune Diseases

Terracina,

Ferraguti,

Tarani

et al. 2023

CIMB

View full text Add to dashboard Cite

show abstract

“…31,32 The significance of high CRP titers and anti-CRP antibodies in active forms of lupus remains requires further investigation. 22,33,34…”

Section: Anti-crp Antibodies and Disease Activity In Slementioning

confidence: 99%

A Review of Anti-C Reactive Protein Antibodies in Systemic Lupus Erythematosus

Richter

Burlui

Bratoiu

et al. 2021

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE), the prototype autoimmune disease, is characterized by the production of a plethora of autoantibodies with various roles in the development of disease-related tissue damage. C-reactive protein (CRP) is an acute phase reactant with a pentameric structure. Under acidic or alkaline conditions, or when urea levels are high and/or calcium levels are low, the pentamer (pCRP) dissociates irreversibly into monomeric CRP (mCRP) and exposes new epitopes (neo-CRP). Importantly, anti-mCRP (but not anti-pCRP) antibodies have been described in patients with SLE, their prevalence varying from 4% to 78% in different cohorts. Numerous studies have investigated the relationship between autoantibodies directed against CRP (anti-CRP) and disease activity as well as their association with lupus nephritis (LN), frequently reporting discrepant findings. The main objective of the present review is to describe the role of anti-mCRP antibodies in SLE according to the currently available data.

show abstract

Increased serum interleukin-34 levels as a novel diagnostic and prognostic biomarker in patients with acute ischemic stroke

Huang

Yang

et al. 2021

Journal of Neuroimmunology

View full text Add to dashboard Cite

Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity

Cited by 6 publications

References 23 publications

Nerve Growth Factor and Autoimmune Diseases

Nerve Growth Factor and Autoimmune Diseases

A Review of Anti-C Reactive Protein Antibodies in Systemic Lupus Erythematosus

Increased serum interleukin-34 levels as a novel diagnostic and prognostic biomarker in patients with acute ischemic stroke

Contact Info

Product

Resources

About